Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, J. C.
Right arrow Articles by Rosenberg, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J. C.
Right arrow Articles by Rosenberg, S. A.
Journal of Clinical Oncology, Vol 21, Issue 16 (August), 2003: 3127-3132
© 2003 American Society for Clinical Oncology

Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer

James C. Yang, Richard M. Sherry, Seth M. Steinberg, Suzanne L. Topalian, Douglas J. Schwartzentruber, Patrick Hwu, Claudia A. Seipp, Linda Rogers-Freezer, Kathleen E. Morton, Donald E. White, David J. Liewehr, Maria J. Merino, Steven A. Rosenberg

From the Surgery Branch, Biostatistics and Data Management Section, Department of Pathology, National Cancer Institute, Bethesda, MD.

Address reprint requests to James C. Yang, MD, Room 2B-37, Building 10, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892; email: james_yang{at}nih.gov.

Purpose: This three-arm randomized study compares response rates and overall survival of patients with metastatic renal cell cancer (RCC) receiving high-dose or one of two low-dose interleukin-2 (IL-2) regimens.

Patients and Methods: Patients with measurable metastatic RCC and a good performance status were randomized to receive either 720,000 U/kg (high-dose [HD]) or 72,000 U/kg (low-dose [LD]), both given by intravenous (IV) bolus every 8 hours. After randomly assigning 117 patients, a third arm of low-dose daily subcutaneous IL-2 was added, and an additional 283 patients were randomly assigned.

Results: A total of 156 patients were randomly assigned to HD IV IL-2, and 150 patients to LD IV IL-2. Toxicities were less frequent with LD IV IL-2 (especially hypotension), but there were no IL-2-related deaths in any arm. There was a higher response proportion with HD IV IL-2 (21%) versus LD IV IL-2 (13%; P = .048) but no overall survival difference. The response rate of subcutaneous IL-2 (10%, partial response and complete response) was similar to that of LD IV IL-2, differing from HD IV (P = .033). Response durability and survival in completely responding patients was superior with HD IV compared with LD IV therapy (P = .04).

Conclusion: Major tumor regressions, as well as complete responses, were seen with all regimens tested. IL-2 was more clinically active at maximal doses, although this did not produce an overall survival benefit. The immunological factors which constrain the curative potential of IL-2 to only a small percentage of patients need to be further elucidated.

Presented at the Society of Biological Therapy Annual Meeting, San Diego, CA, November 8–10, 2002.




This article has been cited by other articles:


Home page
 JCOHome page
B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, D. A. Vaena, S.-S. Ou, L. Archer, J. N. Atkins, J. Picus, P. Czaykowski, et al.
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
J. Clin. Oncol., November 20, 2008; 26(33): 5422 - 5428.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
C. S. Ng, C. G. Wood, P. M. Silverman, N. M. Tannir, P. Tamboli, and C. M. Sandler
Renal Cell Carcinoma: Diagnosis, Staging, and Surveillance
Am. J. Roentgenol., October 1, 2008; 191(4): 1220 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Q. J. Wang, K.-i. Hanada, and J. C. Yang
Characterization of a Novel Nonclassical T Cell Clone with Broad Reactivity against Human Renal Cell Carcinomas
J. Immunol., September 15, 2008; 181(6): 3769 - 3776.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Negrier, D. Perol, A. Ravaud, J. O. Bay, S. Oudard, S. Chabaud, P. Fargeot, R. Delva, G. Deplanque, G. Gravis, et al.
Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFN{alpha} in Patients with Good Prognosis Metastatic Renal Cancer
Clin. Cancer Res., September 15, 2008; 14(18): 5907 - 5912.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. Singla and S. R Denmeade
Left Posterior Fascicular Block Due to High-Dose Interleukin-2
Ann. Pharmacother., September 1, 2008; 42(9): 1340 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. D. Michaelson, O. Iliopoulos, D. F. McDermott, F. J. McGovern, M. G. Harisinghani, and E. Oliva
Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma
N. Engl. J. Med., May 29, 2008; 358(22): 2389 - 2396.
[Full Text] [PDF]

Home page
 J Oncol PractHome page
R. M. Bukowski
How I Treat Renal Cell Carcinoma
J. Oncol. Pract, May 1, 2008; 4(3): 150 - 152.
[Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. Schlom, J. L. Gulley, and P. M. Arlen
Paradigm Shifts in Cancer Vaccine Therapy
Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
J. Schlom, P. M. Arlen, and J. L. Gulley
Immunotherapies with Other Therapeutic Modalities: New Paradigms for Clinical Trial Design
ASCO Educational Book, January 1, 2008; 2008(1): 101 - 106.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. J. Costa and H. A. Drabkin
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Oncologist, December 1, 2007; 12(12): 1404 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Wei, I. Kryczek, R. P. Edwards, L. Zou, W. Szeliga, M. Banerjee, M. Cost, P. Cheng, A. Chang, B. Redman, et al.
Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma
Cancer Res., August 1, 2007; 67(15): 7487 - 7494.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Kato, K. Yoshimura, T. Shin, H. Verheul, H. Hammers, T. B. Sanni, B. C. Salumbides, K. Van Erp, R. Schulick, and R. Pili
Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma
Clin. Cancer Res., August 1, 2007; 13(15): 4538 - 4546.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Schlom, P. M. Arlen, and J. L. Gulley
Cancer Vaccines: Moving Beyond Current Paradigms
Clin. Cancer Res., July 1, 2007; 13(13): 3776 - 3782.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. C. Cesana, F. Romano, G. Piacentini, M. Scotti, A. Brenna, G. Bovo, M. Vaghi, G. Aletti, R. Caprotti, H. Kaufman, et al.
Low-dose Interleukin-2 Administered Pre-operatively to Patients with Gastric Cancer Activates Peripheral and Peritumoral Lymphocytes But Does Not Affect Prognosis
Ann. Surg. Oncol., April 1, 2007; 14(4): 1295 - 1304.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Haferkamp and M. Hohenfellner
Medical treatment options in patients with metastatic renal cell carcinoma
Nephrol. Dial. Transplant., April 1, 2007; 22(4): 996 - 999.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. Krambeck, H. Dong, R. H. Thompson, S. M. Kuntz, C. M. Lohse, B. C. Leibovich, M. L. Blute, T. J. Sebo, J. C. Cheville, A. S. Parker, et al.
Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma
Clin. Cancer Res., March 15, 2007; 13(6): 1749 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Kudo-Saito, E. K. Wansley, M. E. Gruys, R. Wiltrout, J. Schlom, and J. W. Hodge
Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2
Clin. Cancer Res., March 15, 2007; 13(6): 1936 - 1946.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. H. Thompson, H. Dong, and E. D. Kwon
Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy
Clin. Cancer Res., January 15, 2007; 13(2): 709s - 715s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. F. McDermott
Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 716s - 720s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Cho, S. Signoretti, M. Regan, J. W. Mier, and M. B. Atkins
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 758s - 763s.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, et al.
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
N. Engl. J. Med., January 11, 2007; 356(2): 115 - 124.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Lam, A. Breda, A. S. Belldegrun, and R. A. Figlin
Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma
J. Clin. Oncol., December 10, 2006; 24(35): 5565 - 5575.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. C. Yang and R. Childs
Immunotherapy for Renal Cell Cancer
J. Clin. Oncol., December 10, 2006; 24(35): 5576 - 5583.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Parton, M. Gore, and T. Eisen
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
J. Clin. Oncol., December 10, 2006; 24(35): 5584 - 5592.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer and R. M. Bukowski
Targeted Therapy for Metastatic Renal Cell Carcinoma
J. Clin. Oncol., December 10, 2006; 24(35): 5601 - 5608.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Varker, S. V. Kondadasula, M. R. Go, G. B. Lesinski, R. Ghosh-Berkebile, A. Lehman, J. P. Monk, T. Olencki, K. Kendra, and W. E. Carson III
Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets In vitro and following Interleukin-2 Immunotherapy.
Clin. Cancer Res., October 1, 2006; 12(19): 5850 - 5858.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Mirza, M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich
All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients.
Cancer Res., September 15, 2006; 66(18): 9299 - 9307.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Wei, I. Kryczek, and W. Zou
Regulatory T-cell compartmentalization and trafficking
Blood, July 15, 2006; 108(2): 426 - 431.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Cesana, S. Kim-Schulze, and H. L. Kaufman
In Reply
J. Clin. Oncol., July 10, 2006; 24(20): e35 - e36.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. E. Krambeck, R. H. Thompson, H. Dong, C. M. Lohse, E. S. Park, S. M. Kuntz, B. C. Leibovich, M. L. Blute, J. C. Cheville, and E. D. Kwon
B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival
PNAS, July 5, 2006; 103(27): 10391 - 10396.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Huang, K. W. Kerstann, M. Ahmadzadeh, Y. F. Li, M. El-Gamil, S. A. Rosenberg, and P. F. Robbins
Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy.
J. Immunol., June 15, 2006; 176(12): 7726 - 7735.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Wierecky, M. R. Muller, S. Wirths, E. Halder-Oehler, D. Dorfel, S. M. Schmidt, M. Hantschel, W. Brugger, S. Schroder, M. S. Horger, et al.
Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients
Cancer Res., June 1, 2006; 66(11): 5910 - 5918.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Donskov and H. von der Maase
Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma
J. Clin. Oncol., May 1, 2006; 24(13): 1997 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. Doh, A. E. Curtis, B. S. Teh, B. Vincenzi, D. Santini, G. Tonini, H. T. Cohen, and F. J. McGovern
Renal-cell carcinoma.
N. Engl. J. Med., March 9, 2006; 354(10): 1095 - 1096.
[Full Text] [PDF]

Home page
 JCOHome page
G. C. Cesana, G. DeRaffele, S. Cohen, D. Moroziewicz, J. Mitcham, J. Stoutenburg, K. Cheung, C. Hesdorffer, S. Kim-Schulze, and H. L. Kaufman
Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma
J. Clin. Oncol., March 1, 2006; 24(7): 1169 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. T. Cohen and F. J. McGovern
Renal-Cell Carcinoma
N. Engl. J. Med., December 8, 2005; 353(23): 2477 - 2490.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
J. R. Ortaldo, R. T. Winkler-Pickett, E. W. Bere Jr, M. Watanabe, W. J. Murphy, and R. H. Wiltrout
In Vivo Hydrodynamic Delivery of cDNA Encoding IL-2: Rapid, Sustained Redistribution, Activation of Mouse NK Cells, and Therapeutic Potential in the Absence of NKT Cells
J. Immunol., July 15, 2005; 175(2): 693 - 699.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Aass, P. H.M. De Mulder, G. H.J. Mickisch, P. Mulders, A. T. van Oosterom, H. van Poppel, S. D. Fossa, L. de Prijck, and R. J. Sylvester
Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-cis-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)
J. Clin. Oncol., June 20, 2005; 23(18): 4172 - 4178.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. A. Erdmann, Z.-G. Gao, U. Jung, J. Foley, T. Borenstein, K. A. Jacobson, and D. H. Fowler
Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo
Blood, June 15, 2005; 105(12): 4707 - 4714.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Hoving, F. Brunstein, G. aan de Wiel-Ambagtsheer, S. T. van Tiel, G. de Boeck, E. A. de Bruijn, A. M.M. Eggermont, and T. L.M. ten Hagen
Synergistic Antitumor Response of Interleukin 2 with Melphalan in Isolated Limb Perfusion in Soft Tissue Sarcoma-Bearing Rats
Cancer Res., May 15, 2005; 65(10): 4300 - 4308.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Atkins, M. Regan, D. McDermott, J. Mier, E. Stanbridge, A. Youmans, P. Febbo, M. Upton, M. Lechpammer, and S. Signoretti
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Clin. Cancer Res., May 15, 2005; 11(10): 3714 - 3721.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. Spanknebel, K. Y. Cheung, J. Stoutenburg, K. Hurst-Wicker, C. Hesdorffer, G. DeRaffele, and H. L. Kaufman
Initial Clinical Response Predicts Outcome and Is Associated With Dose Schedule in Metastatic Melanoma and Renal Cell Carcinoma Patients Treated With High-Dose Interleukin 2
Ann. Surg. Oncol., May 1, 2005; 12(5): 381 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. Katz-Brull, N. M. Rofsky, M. M. Morrin, I. Pedrosa, D. J. George, M. D. Michaelson, R. P. Marquis, M. Maril, C. Noguera, and R. E. Lenkinski
Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy
Am J Physiol Renal Physiol, April 1, 2005; 288(4): F637 - F641.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood, February 15, 2005; 105(4): 1383 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. I. Rini and E. J. Small
Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma
J. Clin. Oncol., February 10, 2005; 23(5): 1028 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. F. McDermott, M. M. Regan, J. I. Clark, L. E. Flaherty, G. R. Weiss, T. F. Logan, J. M. Kirkwood, M. S. Gordon, J. A. Sosman, M. S. Ernstoff, et al.
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., January 1, 2005; 23(1): 133 - 141.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Salcedo, J. K. Stauffer, E. Lincoln, T. C. Back, J. A. Hixon, C. Hahn, K. Shafer-Weaver, A. Malyguine, R. Kastelein, and J. M. Wigginton
IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells
J. Immunol., December 15, 2004; 173(12): 7170 - 7182.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. H. Thompson, M. D. Gillett, J. C. Cheville, C. M. Lohse, H. Dong, W. S. Webster, K. G. Krejci, J. R. Lobo, S. Sengupta, L. Chen, et al.
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
PNAS, December 7, 2004; 101(49): 17174 - 17179.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Atkins, M. Regan, and D. McDermott
Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma
Clin. Cancer Res., September 15, 2004; 10(18): 6342S - 6346S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-J. Patard, H. L. Kim, J. S. Lam, F. J. Dorey, A. J. Pantuck, A. Zisman, V. Ficarra, K.-R. Han, L. Cindolo, A. De La Taille, et al.
Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study
J. Clin. Oncol., August 15, 2004; 22(16): 3316 - 3322.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. K. Rowinsky, G. H. Schwartz, J. A. Gollob, J. A. Thompson, N. J. Vogelzang, R. Figlin, R. Bukowski, N. Haas, P. Lockbaum, Y.-P. Li, et al.
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
J. Clin. Oncol., August 1, 2004; 22(15): 3003 - 3015.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Negrier
Better Survival With Interleukin-2-Based Regimens? Possibly Only in Highly Selected Patients
J. Clin. Oncol., April 1, 2004; 22(7): 1174 - 1176.
[Full Text] [PDF]

Home page
 Integr Cancer TherHome page
S. K. Gupta and N. Vogelzang
Integrative Tumor Board: Metastatic Renal Cell Carcinoma
Integr Cancer Ther, March 1, 2004; 3(1): 26 - 29.
[PDF]

Home page
 Integr Cancer TherHome page
D. Rubin
Integrative Tumor Board: Metastatic Renal Cell Carcinoma
Integr Cancer Ther, March 1, 2004; 3(1): 34 - 41.
[PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online